Raymond James on Vera Therapeutics (VERA): 'we don’t think this is a referendum on the overall efficacy of these drugs in IgAN'
Tweet Send to a Friend
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $73.00 price target on Vera Therapeutics (NASDAQ: VERA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
